PMID- 33577738
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 1744-5116 (Electronic)
IS  - 1388-0209 (Print)
IS  - 1388-0209 (Linking)
VI  - 59
IP  - 1
DP  - 2021 Dec
TI  - Evodiamine protects against airway remodelling and inflammation in asthmatic rats 
      by modulating the HMGB1/NF-kappaB/TLR-4 signalling pathway.
PG  - 192-199
LID - 10.1080/13880209.2020.1871374 [doi]
AB  - CONTEXT: Evodiamine, which is isolated from Evodia rutaecarpa (Rutaceae), possess 
      strong anti-inflammatory, immunomodulatory, and antibacterial properties. 
      OBJECTIVE: The protective effects of evodiamine in asthma were evaluated. 
      MATERIALS AND METHODS: Thirty-two Sprague-Dawley (SD) rats were used, asthma was 
      induced by injecting intraperitoneally with a mixture of Al(OH)(3) (100 mg) and 
      ovalbumin (OA; 1 mg/kg), further exposing them to a 2% OA aerosol for 1 week. All 
      animals were divided into four groups: control, asthma, and evodiamine 40 and 
      80 mg/kg p.o. treated group. Serum levels of inflammatory cytokines, interferon 
      gamma (IFN-gamma), and immunoglobulin E (IgE) and infiltrations of inflammatory cells 
      in the bronchoalveolar lavage fluid (BALF) of the animals were determined. The 
      thickness of the smooth muscle layer and airway wall in the intact small 
      bronchioles of asthmatic rats was examined as well. RESULTS: Cytokine levels in 
      the serum and BALF were lower in the evodiamine-treated group than in the asthma 
      group. Evodiamine treatment reduced IgE and IFN-gamma levels as well as the 
      inflammatory cell infiltrate in the lung tissue of asthmatic rats. The thickness 
      of the smooth muscle layer and airway wall of intact small bronchioles was less 
      in the evodiamine-treated group than in the asthma group. Lower levels of TLR-4, 
      MyD88, NF-kappaB, and HMGB1 mRNA in lung tissue were measured in the 
      evodiamine-treated group than in the asthma group. DISCUSSION AND CONCLUSION: The 
      effect of evodiamine treatment protects the asthma, as evodiamine reduces airway 
      inflammation and remodelling in the lung tissue by downregulating the 
      HMGB1/NF-kappaB/TLR-4 pathway in asthma.
FAU - Wang, Qiong
AU  - Wang Q
AD  - Department of Clinical Laboratory, Wuxi People's Hospital Affiliated to Nanjing 
      Medical University, Jiangsu, China.
FAU - Cui, Yubao
AU  - Cui Y
AD  - Department of Clinical Laboratory, Wuxi People's Hospital Affiliated to Nanjing 
      Medical University, Jiangsu, China.
FAU - Wu, Xufeng
AU  - Wu X
AD  - Department of Chinese Traditional Medicine, Wuxi People's Hospital Affiliated to 
      Nanjing Medical University, Jiangsu, China.
FAU - Wang, Junfang
AU  - Wang J
AD  - Department of Orthopaedics, Wuxi People's Hospital Affiliated to Nanjing Medical 
      University, Jiangsu, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pharm Biol
JT  - Pharmaceutical biology
JID - 9812552
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cytokines)
RN  - 0 (HMGB1 Protein)
RN  - 0 (Hbp1 protein, rat)
RN  - 0 (NF-kappa B)
RN  - 0 (Quinazolines)
RN  - 0 (Tlr4 protein, rat)
RN  - 0 (Toll-Like Receptor 4)
RN  - C01825BVNL (evodiamine)
SB  - IM
MH  - Airway Remodeling/*drug effects
MH  - Animals
MH  - Anti-Inflammatory Agents/administration & dosage/isolation & 
      purification/pharmacology
MH  - Asthma/*drug therapy/physiopathology
MH  - Bronchoalveolar Lavage Fluid
MH  - Cytokines/metabolism
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Evodia/chemistry
MH  - HMGB1 Protein/metabolism
MH  - Inflammation/*drug therapy/pathology
MH  - NF-kappa B/metabolism
MH  - Quinazolines/administration & dosage/isolation & purification/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Signal Transduction/drug effects
MH  - Toll-Like Receptor 4/metabolism
PMC - PMC7889089
OTO - NOTNLM
OT  - Asthma
OT  - bronchioles
OT  - cytokine
OT  - lung
COIS- The authors report no declarations of interest. The authors alone are responsible 
      for the content and writing of the paper.
EDAT- 2021/02/13 06:00
MHDA- 2021/09/21 06:00
PMCR- 2021/02/12
CRDT- 2021/02/12 20:10
PHST- 2021/02/12 20:10 [entrez]
PHST- 2021/02/13 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2021/02/12 00:00 [pmc-release]
AID - 1871374 [pii]
AID - 10.1080/13880209.2020.1871374 [doi]
PST - ppublish
SO  - Pharm Biol. 2021 Dec;59(1):192-199. doi: 10.1080/13880209.2020.1871374.